Venture
Pharmaceutics International, Inc.
Latest Form D 2024-10-23- CIK 1684470
- State MD
- Pharmaceuticals
- 17 Form D offerings since 2016-09-14
- Total sold
- $206M
- across 17 offerings
- Rounds
- 17
- Form D offerings since 2016-09-14
- Latest round
- $11.2M
- 2024-06-11 · 021-515696
- Investors
- 3
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2024-06-11 · $11.2M
- 2016-09-14$108M021-270603
- 2017-08-15$10M021-292783
- 2018-10-29$6M021-324528
- 2021-06-04$3M021-401840
- 2021-06-04$10M021-401842
- 2021-08-06$6M021-409139
- 2021-10-29$5M021-419195
- 2022-01-11$5M021-428816
- 2022-03-17$5M021-437813
- 2022-05-05$5M021-444518
- 2022-07-12$5M021-451912
- 2022-08-22$5M021-456510
- 2022-10-07$9M021-461091
- 2022-12-12$3M021-467195
- 2023-06-27$6M021-485220
- 2024-03-13$4.2M021-507436
- 2024-06-11$11.2M021-515696
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($108M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-515696 | First filed2024-06-11 | Latest2024-10-23 | Sought$11.2M | Sold$11.2M | Investors3 | Exemptions506(b) |
| 021-507436 | First filed2024-03-13 | Latest2024-03-13 | Sought$4.2M | Sold$4.2M | Investors6 | Exemptions506(b) |
| 021-485220 | First filed2023-06-27 | Latest2023-06-27 | Sought$12M | Sold$6M | Investors2 | Exemptions506(b) |
| 021-467195 | First filed2022-12-12 | Latest2022-12-12 | Sought$3M | Sold$3M | Investors5 | Exemptions506(b) |
| 021-461091 | First filed2022-10-07 | Latest2022-10-07 | Sought$9M | Sold$9M | Investors5 | Exemptions506(b) |
| 021-456510 | First filed2022-08-22 | Latest2022-08-22 | Sought$5M | Sold$5M | Investors5 | Exemptions506(b) |
| 021-451912 | First filed2022-07-12 | Latest2022-07-12 | Sought$5M | Sold$5M | Investors5 | Exemptions506(b) |
| 021-444518 | First filed2022-05-05 | Latest2022-05-05 | Sought$5M | Sold$5M | Investors4 | Exemptions506(b) |
| 021-437813 | First filed2022-03-17 | Latest2022-03-17 | Sought$5M | Sold$5M | Investors4 | Exemptions506(b) |
| 021-428816 | First filed2022-01-11 | Latest2022-01-11 | Sought$5M | Sold$5M | Investors2 | Exemptions506(b) |
| 021-419195 | First filed2021-10-29 | Latest2021-10-29 | Sought$5M | Sold$5M | Investors2 | Exemptions506(b) |
| 021-409139 | First filed2021-08-06 | Latest2021-08-06 | Sought$6M | Sold$6M | Investors5 | Exemptions506(b) |
| 021-401842 | First filed2021-06-04 | Latest2021-06-04 | Sought$10M | Sold$10M | Investors6 | Exemptions506(b) |
| 021-401840 | First filed2021-06-04 | Latest2021-06-04 | Sought$3M | Sold$3M | Investors4 | Exemptions506(b) |
| 021-324528 | First filed2018-10-29 | Latest2018-10-29 | Sought$15M | Sold$6M | Investors5 | Exemptions506(b) |
| 021-292783 | First filed2017-08-15 | Latest2017-08-15 | Sought$20M | Sold$10M | Investors6 | Exemptions506(b) |
| 021-270603 | First filed2016-09-14 | Latest2016-09-14 | Sought$108M | Sold$108M | Investors9 | Exemptions506(b) |
Who backs Pharmaceutics International, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2024-10-23
| Name | Relationship |
|---|---|
| Syed E Abidi, Ph.D. | RelationshipDirector |
| Mark Kavulich | RelationshipDirector |
| Michael Bogda | RelationshipDirector |
| David Solomon | RelationshipDirector |
| John Fowler | RelationshipExecutive Officer, Director |
| James Gale | RelationshipDirector |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| Teneo Securities LLC | CRD151256 | Broker-dealer— | Offerings1 |
Facts
As its latest Form D states them
- Industry
- Pharmaceuticals
- State
- Maryland (MD)
- Exemptions
- Rule 506(b)
- First filed
- 2016-09-14
- Latest filing
- 2024-10-23
Who backs Pharmaceutics International, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗